PMID- 15167972
OWN - NLM
STAT- MEDLINE
DCOM- 20050106
LR  - 20161124
IS  - 1023-3830 (Print)
IS  - 1023-3830 (Linking)
VI  - 53
IP  - 6
DP  - 2004 Jun
TI  - An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured 
      endothelial cells of coronary arteries in vitro.
PG  - 253-6
AB  - OBJECTIVE: Kawasaki disease (KD) is an acute febrile vasculitis of unknown 
      etiology that may lead to cardiovascular disorders. High-dose intravenous 
      immunoglobulin (IVIG) therapy is well established as a standard therapy for KD. 
      Tumor necrosis factor-alpha (TNF-alpha) is responsible for the pathogenesis of 
      acute KD. We examined whether or not IVIG inhibits TNF-alpha-induced activation 
      of transcription factor NF-kappaB, a factor that is essential for the expression 
      of proinflammatory cytokines, in human coronary artery endothelial cells (CAEC). 
      METHODS: The inhibitory effect of IVIG on NF-kappaB activation induced by 
      TNF-alpha was evaluated by Western blot analysis and ELISA. Moreover, the 
      inhibitory effects of IVIG on IkappaBalpha degradation, interleukin-6 (IL-6) 
      production, and E-selectin expression induced by TNF-alpha were evaluated by 
      Western blot analysis, ELISA, and flow cytometry, respectively. RESULTS: Western 
      blot analysis and ELISA demonstrated that IVIG inhibits NF-kappaB activation 
      induced by TNF-alpha in CAEC. Moreover, IVIG inhibited IkappaBalpha degradation, 
      IL-6 production, and E-selectin expression induced by TNF-alpha in CAEC. 
      CONCLUSION: The data suggest that IVIG inhibits NF-kappaB activation induced by 
      TNF-alpha in CAEC, thereby possibly modulating IL-6 production and E-selectin 
      expression.
FAU - Ichiyama, T
AU  - Ichiyama T
AD  - Department of Pediatrics, Yamaguchi University School of Medicine, 1-1-1 
      Minami-kogushi, Ube, Yamaguchi 755-8505, Japan. ichiyama@yamaguchi-u.ac.jp
FAU - Ueno, Y
AU  - Ueno Y
FAU - Isumi, H
AU  - Isumi H
FAU - Niimi, A
AU  - Niimi A
FAU - Matsubara, T
AU  - Matsubara T
FAU - Furukawa, S
AU  - Furukawa S
LA  - eng
PT  - Journal Article
DEP - 20040512
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Cytokines)
RN  - 0 (E-Selectin)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Interleukin-6)
RN  - 0 (NF-kappa B)
RN  - 0 (NFKBIA protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
SB  - IM
MH  - Arteries/cytology
MH  - Blotting, Western
MH  - Cell Nucleus/metabolism
MH  - Cells, Cultured
MH  - Coronary Vessels/cytology
MH  - Cytokines/metabolism
MH  - Cytoplasm/metabolism
MH  - E-Selectin/metabolism
MH  - Endothelium, Vascular/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Flow Cytometry
MH  - Humans
MH  - I-kappa B Proteins/metabolism
MH  - Immunoglobulins, Intravenous/*chemistry/*pharmacology
MH  - Interleukin-6/metabolism
MH  - NF-KappaB Inhibitor alpha
MH  - NF-kappa B/*metabolism
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2004/05/29 05:00
MHDA- 2005/01/07 09:00
CRDT- 2004/05/29 05:00
PHST- 2003/09/29 00:00 [received]
PHST- 2004/01/07 00:00 [accepted]
PHST- 2004/05/29 05:00 [pubmed]
PHST- 2005/01/07 09:00 [medline]
PHST- 2004/05/29 05:00 [entrez]
AID - 10.1007/s00011-004-1255-3 [doi]
PST - ppublish
SO  - Inflamm Res. 2004 Jun;53(6):253-6. doi: 10.1007/s00011-004-1255-3. Epub 2004 May 
      12.